Urotensin II and renal function in the rat

Kidney International

Volumn 69, Issue 8, 2006, Pages 1360-1368

  Song, W ^a   Abdel Razik, A E S ^a   Lu, W ^a   Ao, Z ^b   Johns, D G ^b   Douglas, S A ^b   Balment, R J ^a   Ashton, N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

GFR; Sodium; Spontaneously hypertensive rat; Urotensin II; Urotensin related peptide; UT receptor

Indexed keywords

CALCIUM ION; MAGNESIUM ION; MESSENGER RNA; POTASSIUM ION; RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; SODIUM ION; UNCLASSIFIED DRUG; URANTIDE; UROTENSIN II; UROTENSIN II RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY MEDULLA; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; GLOMERULAR FILTRATION RATE; HEMODYNAMIC PROCESSES; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; PEPTIDE FRAGMENTS; RADIOIMMUNOASSAY; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECIES SPECIFICITY; UROTENSINS;

EID: 33646123786     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000290     Document Type: Article

References (46)

1. Bern HA, Pearson D, Larson BA et al. Neurohormones from fish tails: the caudal neurosecretory system. I. 'Urophysiology' and the caudal neurosecretory system of fishes. Recent Prog Horm Res 1985; 41: 533-552.
2. Coulouarn Y, Lihrmann I, Jegou S et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 1998; 95: 15803-15808.
3. Ames RS, Sarau HM, Chambers JK et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401: 282-286.
4. Liu Q, Pong SS, Zeng Z et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999; 266: 174-178.
5. Douglas SA, Ohlstein EH. Urotensin receptors. In: Girdlestone D (eds) The IUPHAR Compendium of Receptor Characterization and Classification. IUPHAR Media: London, 2000 pp 365-372.
6. Wilkinson IB, Affolter JT, de Haas SL et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002; 53: 341-347.
7. Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002; 135: 25-27.
8. Hillier C, Berry C, Petrie MC et al. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 2001; 103: 1378-1381.
9. Douglas SA, Sulpizio AC, Piercy V et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000; 131: 1262-1274.
10. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000; 131: 441-446.
11. Labarrere P, Chatenet D, Leprince J et al. Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J Enzyme Inhib Med Chem 2003; 18: 77-88.
12. Grieco P, Rovero P, Novellino E. Recent structure-activity studies of the peptide hormone urotensin-II, a potent vasoconstrictor. Curr Med Chem 2004; 11: 969-979.
13. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000; 10: 229-237.
14. Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol 2002; 137: 579-588.
15. Douglas SA, Dhanak D, Johns DG. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004; 25: 76-85.
16. Russell FD. Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther 2004; 103: 223-243.
17. Loretz CA, Freel RW, Bern HA. Specificity of response of intestinal ion transport systems to a pair of natural peptide hormone analogs: somatostatin and urotensin II. Gen Comp Endocrinol 1983; 52: 198-206.
18. Bond H, Winter MJ, Warne JM et al. Plasma concentrations of arginine vasotocin and urotensin II are reduced following transfer of the euryhaline flounder (Platichthys flesus) from seawater to fresh water. Gen Comp Endocrinol 2002; 125: 113-120.
19. Marshall WS, Bern HA. Teleostean urophysis: urotensin II and ion transport across the isolated skin of a marine teleost. Science 1979; 204: 519-521.
20. Baldisserotto B, Mimura OM. Changes in the electrophysiological parameters of the posterior intestine of Anguilla anguilla (Pisces) induced by oxytocin, urotensin II and aldosterone. Braz J Med Biol Res 1997; 30: 35-39.
21. Loretz CA. Species specificity and cellular mechanism of action of urotensin II in osmoregulation. In: Kobayashi H, Bern HA, Urano A (eds) Neurosecretion and the Biology of Neuropeptides. Springer-Verlag: Berlin, 1985 pp 479-485.
22. Totsune K, Takahashi K, Arihara Z et al. Role of urotensin II in patients on dialysis. Lancet 2001; 358: 810-811.
23. Matsushita M, Shichiri M, Imai T et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001; 19: 2185-2190.
24. Elshourbagy NA, Douglas SA, Shabon U et al. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 2002; 136: 9-22.
25. Nothacker HP, Wang Z, McNeill AM et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1999; 1: 383-385.
26. Shenouda A, Douglas SA, Ohlstein EH et al. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 2002; 50: 885-889.
27. Maguire JJ, Kuc RE, Wiley KE et al. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004; 25: 1767-1774.
28. Totsune K, Takahashi K, Arihara Z et al. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003; 104: 1-5.
29. Coulouarn Y, Jegou S, Tostivint H et al. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 1999; 457: 28-32.
30. Tal M, Ammar DA, Karpuj M et al. A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem Biophys Res Commun 1995; 209: 752-759.
31. Sugo T, Murakami Y, Shimomura Y et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 2003; 310: 860-868.
32. Zhang AY, Chen YF, Zhang DX et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003; 285: F792-F798.
33. Patacchini R, Santicioli P, Giuliani S et al. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol 2003; 140: 1155-1158.
34. Cheung BM, Leung R, Man YB et al. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004; 22: 1341-1344.
35. Gardiner SM, March JE, Kemp PA et al. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 2001; 132: 1625-1629.
36. Camarda V, Song W, Marzola E et al. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol 2004; 498: 83-86.
37. Medakovic M, Chan DK, Lederis K. Pharmacological effects of urotensins. I. Regional vascular effects of urotensins I and II in the rat. Pharmacology 1975; 13: 409-418.
38. Loretz CA, Bern HA. Stimulation of sodium transport across the teleost urinary bladder by urotensin II. Gen Comp Endocrinol 1981; 43: 325-330.
39. Mainoya JR, Bern HA. Effects of teleost urotensins on intestinal absorption of water and NaCl in Tilapia, Sarotherodon mossambicus, adapted to fresh water or seawater. Gen Comp Endocrinol 1982; 47: 54-58.
40. Totsune K, Takahashi K, Arihara Z et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004; 25: 1809-1814.
41. Gilbert RE, Douglas SA, Krum H. Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease. Curr Opin Invest Drugs 2004; 5: 276-282.
42. Winter MJ, Hubbard PC, McCrohan CR et al. A homologous radio-immunoassay for the measurement of urotensin II in the euryhaline flounder, Platichthys flesus. Gen Comp Endocrinol 1999; 114: 249-256.
43. Balment RJ, Song W, Ashton N. Urotensin II: ancient hormone with new functions in vertebrate body fluid regulation. Ann NY Acad Sci 2005; 1040: 66-73.
44. Fraker PJ, Speck Jr JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-857.
45. Nielsen S, Frokiaer J, Marples D et al. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002; 82: 205-244.
46. 1 receptor expression in young rats following intrauterine exposure to a maternal low-protein diet. Clin Sci (Lond) 2003; 104: 607-614.